SEC Comment Letter 0000000000-23-006159 to OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715) (OKUR)
OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715)
Date: June 8, 2023 · CIK: 0001637715 · Accession: 0000000000-23-006159
AI Filing Summary & Sentiment
File numbers found in text: 333-272421
Letter
United States securities and exchange commission logo June 8, 2023 Gregory Flesher President and Chief Executive Officer Reneo Pharmaceuticals, Inc. 18575 Jamboree Road, Suite 275-S Irvine, California 92612 Re:Reneo Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 5, 2023 File No. 333-272421 Dear Gregory Flesher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason Kent
Show Raw Text
United States securities and exchange commission logo
June 8, 2023
Gregory Flesher
President and Chief Executive Officer
Reneo Pharmaceuticals, Inc.
18575 Jamboree Road, Suite 275-S
Irvine, California 92612
Re:Reneo Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 5, 2023
File No. 333-272421
Dear Gregory Flesher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jason Kent